Receive our newsletter – data, insights and analysis delivered to you
June 8, 2009

GSK’s Rotarix Vaccine Given Global WHO Prequalification

The World Health Organization (WHO) has awarded global prequalification to Rotarix, a rotavirus vaccine produced by GlaxoSmithKline (GSK). Rotarix is already registered in more than 100 countries worldwide, and is approved by major regulatory agencies such as the European Medicines Agency

By cms admin

The World Health Organization (WHO) has awarded global prequalification to Rotarix, a rotavirus vaccine produced by GlaxoSmithKline (GSK).

Rotarix is already registered in more than 100 countries worldwide, and is approved by major regulatory agencies such as the European Medicines Agency and the US Food and Drug Administration.

GSK Biologicals CEO Jean Stephenne said that today’s approval is the culmination of a long-standing commitment at GSK to deliver a rotavirus vaccine for the world.

“Five years ago, GSK pursued a different regulatory strategy to speed the availability of Rotarix by introducing the vaccine in developing countries first, where the medical needs and mortality rates are highest,” he added.

GSK Biologicals has now launched Rotarix in Latin America as part of the new ‘South-first’ access strategy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU